US Stock Insider Trading | Seer disclosed two insider trading transactions on February 19

K-LinePoet · 2026-02-22T23:58:50+00:00

Seer disclosed internal trading activities on February 19, 2026. Director Farokhzad Omid and executive Horn David R. sold 24,400 shares and 7,743 shares respectively on February 18. In addition, the company focuses on providing bioinformatics services, with products including a protein map product suite.

K-LinePoet

2026-02-22 23:58:50

Abstract generation in progress

On February 19, 2026, Seer (SEER) disclosed two insider trading transactions. Director Farokhzad Omid sold 24,400 shares on February 18, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 19, 2026	Executive	Horn David R.	February 18, 2026	Sell	7,743	1.99	15,400
February 19, 2026	Director	Farokhzad Omid	February 18, 2026	Sell	24,400	1.99	48,600
November 21, 2025	Executive	Horn David R.	November 19, 2025	Sell	6,797	1.97	13,400
November 21, 2025	Director	Farokhzad Omid	November 19, 2025	Sell	33,800	1.97	66,700
August 21, 2025	Director	Farokhzad Omid	August 20, 2025	Sell	34,000	2.04	69,500
August 21, 2025	Executive	Horn David R.	August 20, 2025	Sell	6,827	2.04	14,000
June 16, 2025	Director	Nishar Dipchand	June 13, 2025	Sell	30,300	2.08	62,900
May 22, 2025	Executive	Horn David R.	May 20, 2025	Sell	6,760	2.08	14,000
May 22, 2025	Director	Farokhzad Omid	May 20, 2025	Sell	33,700	2.08	69,900
February 20, 2025	Executive	Horn David R.	February 18, 2025	Sell	26,600	2.30	61,100

[Company Information]

Seer, Inc. was incorporated on March 16, 2017, in Delaware. The company’s goal is to enable researchers to achieve outstanding scientific results by commercializing transformative products that provide deep, unbiased biological information. Its initial product, the Proteograph Protein Graph Platform, leverages proprietary engineered nanoparticle (NP) technology to offer unbiased, in-depth, rapid, and high-throughput access across the proteome. The Proteograph platform is an integrated solution consisting of consumables, automated instruments, and software. It provides an easy-to-use workflow capable of proteomics analysis and the characterization of the complex, dynamic proteome across thousands of samples, accessible to nearly any laboratory.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes